InveniAI® has received a milestone payment from Kyowa Kirin under the research collaboration between the companies.
Yoshifumi Torii, Ph.D., Executive Officer, Vice President, and Head of R&D Division of Kyowa Kirin, said, “We are excited to achieve a successful outcome by leveraging InveniAI’s platform AlphaMeld® that detected very early signals of association between targets/mechanism of action and clinical utility based on the platform’s analytics.”
“We are delighted with the progress of our synergistic collaboration with Kyowa Kirin and the advancement of an AI-identified target and associated clinical utility at unprecedented speed,” said InveniAI’s President and Chief Executive Officer, Krishnan Nandabalan, Ph.D.